Revumenib sheds light on AML patients as the drug potentially treats their cancer. A group of researchers conducted phase one of clinical trials between 2019 to 2022 for an anti-cancer drug on patients living with acute myeloid leukemia (AML).
Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.
Surging incidence rate of different types of cancer such as beast cancer, liver cancer, skin cancer and much more is directly propelling the demand for.